POINT Biopharma Global Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a PNT research report →
Range $10 – $17
Price Chart
About the company
POINT Biopharma Global Inc. functions as a radiopharmaceutical company dedicated to the advancement and commercialization of specialized radioligand therapies designed to combat various cancerous conditions. Its two primary investigational treatments, both currently in Phase III clinical trials, are PNT2002, a radioligand engineered to target prostate-specific membrane antigen (PSMA) for addressing metastatic castration-resistant prostate cancer, and PNT2003, a somatostatin-targeted radioligand being evaluated for the treatment of neuroendocrine tumors.
- CEO
- Joe A. McCann
- IPO
- 2020
- Employees
- 129
- HQ
- Indianapolis, IN, US
Get TickerSpark's AI analysis on PNT
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.33B
- P/E
- 12.02
- PEG
- 0.05
- P/S
- 5.88
- P/B
- 2.43
- EV/EBITDA
- 8.21
- Div Yield
- 0.00%
- Gross Margin
- 100.00%
- Op Margin
- 55.40%
- Net Margin
- 43.38%
- ROE
- 26.49%
- ROIC
- 19.10%
Latest fiscal year · YoY change
- Revenue
- $226.58M+0.0%
- Gross Profit
- $226.58M+0.0%
- Op Income
- $125.52M
- Net Income
- $98.29M+314.1%
- EPS
- $1.04+267.7%
- OCF Growth
- +510.6%
- FCF Growth
- +419.2%
- 52W High
- $14.35
- 52W Low
- $6.57
- 50D MA
- $13.22
- 200D MA
- $9.77
- Beta
- -0.00
- RSI (14)
- 35
- Avg Volume
- 3.85M
No earnings-call transcripts are available for PNT yet.
- Free Float
- 82.1%
- Shares Outstanding
- 106.57M
- Float Shares
- 87.47M
of shares held by institutions
132 13F filers
Buy/sell ratio 0.00. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| First Republic Investment Management, Inc. | 20.00K | 0 |
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Dec 27, 23 | GOODMAN JONATHAN R. | sell | 44,749 |
| Dec 26, 23 | GOODMAN JONATHAN R. | other | 41,872 |
| Dec 27, 23 | GOODMAN JONATHAN R. | sell | 35,872 |
| Dec 27, 23 | GOODMAN JONATHAN R. | sell | 25,000 |
| Dec 27, 23 | GOODMAN JONATHAN R. | sell | 25,614 |
| Dec 27, 23 | KELLY JUSTYNA | sell | 26,904 |
| Dec 27, 23 | KELLY JUSTYNA | sell | 4,932 |
| Dec 27, 23 | KELLY JUSTYNA | sell | 77,958 |
| Dec 27, 23 | KELLY JUSTYNA | sell | 98,358 |
| Dec 27, 23 | KELLY JUSTYNA | sell | 70,000 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our PNT coverage
Recent articles, reports, and earnings notes.
No research on PNT yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate PNT report →Furuno Unveils New SOLION-100 Terminal for Iridium GMDSS
gurufocus.com · Sep 1
Iridium's PNT ASIC: A New Catalyst Beyond Satellite Connectivity?
zacks.com · Jul 17
Iridium Announces Commercial Availability of Iridium PNT ASIC, Bringing Resilient GNSS Protection to Devices Worldwide
prnewswire.com · Jul 14
Iridium NTN Direct Begins Live Testing with Mlink
prnewswire.com · Jun 24
Iridium's Next‑Generation Hybrid IoT Module and Development Kit are Now Commercially Available
prnewswire.com · Jun 23
NextNav Announces Redemption of 5.00% Senior Secured Convertible Notes
businesswire.com · Jun 15
NextNav Aims for Safe Drone-dominant Future with GSMA and Industry Partners
gurufocus.com · Jun 10
NextNav Announces Redemption of Public Warrants
gurufocus.com · May 27
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.